Compare NWPX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWPX | ENGN |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.9M | 605.5M |
| IPO Year | 1995 | N/A |
| Metric | NWPX | ENGN |
|---|---|---|
| Price | $74.67 | $9.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $60.00 | $22.71 |
| AVG Volume (30 Days) | 91.2K | ★ 473.3K |
| Earning Date | 02-25-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.50 | N/A |
| EPS | ★ 3.66 | N/A |
| Revenue | ★ $519,991,000.00 | N/A |
| Revenue This Year | $8.18 | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | ★ 7.64 | N/A |
| 52 Week Low | $36.97 | $2.65 |
| 52 Week High | $77.43 | $12.25 |
| Indicator | NWPX | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.92 | 53.30 |
| Support Level | $68.13 | $9.30 |
| Resistance Level | $77.43 | $10.20 |
| Average True Range (ATR) | 2.44 | 0.88 |
| MACD | 0.32 | -0.07 |
| Stochastic Oscillator | 63.53 | 41.30 |
NWPX Infrastructure Inc is a manufacturer of water-related infrastructure products. The Company is the manufacturer of engineered water transmission systems in North America and produces steel casing pipe, bar-wrapped concrete cylinder pipe, and pipeline system joints and fittings through its Engineered Steel Pressure Pipe segment. The Company provides solution-based products for a wide range of markets, including high-quality reinforced precast concrete products, lined precast sanitary sewer system components, water distribution and management equipment, including pump lift stations, wastewater pretreatment, and stormwater quality products through its Precast Infrastructure and Engineered Systems segment.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.